VRNA — Verona Pharma Balance Sheet
0.000.00%
- $7.85bn
- $7.69bn
- $42.28m
Annual balance sheet for Verona Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 188 | 148 | 228 | 272 | 400 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 8.26 | 15.6 | 9.28 | 11 | 37.3 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 203 | 170 | 243 | 290 | 454 |
Net Property, Plant And Equipment | 1.16 | 0.979 | 0.927 | 2.87 | 3.15 |
Net Goodwill | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 204 | 187 | 259 | 308 | 474 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 14.2 | 33.4 | 19 | 8.69 | 42.7 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 19.4 | 38.6 | 29 | 58.8 | 270 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 185 | 148 | 230 | 249 | 205 |
Total Liabilities & Shareholders' Equity | 204 | 187 | 259 | 308 | 474 |
Total Common Shares Outstanding |